Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...
How a skin drug trial could help Peninsula biotech pull off key merger
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Alumis announces data from the OLE of its Phase 2 STRIDE trial
Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...
Managed Healthcare Executive3d
The 2025 AAD Meeting is Underway | AAD 2025
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Managed Healthcare Executive3d
The2025 AAD Meeting is Underway
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
BioSpace5d
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.
Fierce Biotech6d
Acelyrin doubles down on Alumis merger after deciding Concentra's surprise offer 'not superior'
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...
ACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, ...
Morningstar6d
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
These programs, including ESK-001 in moderate-to-severe plaque psoriasis and systemic lupus erythematosus, lonigutamab for thyroid eye disease, and A-005 in multiple sclerosis, offer multiple ...